Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Assessing potential allergic reactions in COVID-19 vaccinated patients

Researchers analyze suspected reactions in patients vaccinated with the first and/or second dose of SARS-CoV-2 vaccines.

13 Feb 2022

Two peanut allergy treatments for children found to be highly effective at inducing remission

Researchers have discovered two peanut allergy treatments for children that are both highly effective at inducing remission.

7 Feb 2022

Vaccine hypersensitivity in children

A new paper published in Pediatric Allergy and Immunity provides a useful overview of such reactions in relation to pediatric vaccines.

31 Jan 2022

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

The majority of young children treated with peanut immunotherapy achieved desensitization after two and a half years of treatment, and one in five remained in remission 26 weeks after treatment ended, according to a randomized controlled trial published in The Lancet.

20 Jan 2022

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

A growing body of evidence indicates that some people thought to have an allergic response to injectable penicillin, the standard treatment for rheumatic heart disease, may instead be experiencing a cardiac reaction to the medicine, according to a new American Heart Association presidential advisory published today in Journal of the American Heart Association.

19 Jan 2022

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

In a new study, a team of researchers conducted a case-control study at a mass vaccination center in Japan to evaluate acute and long-term adverse events following immunization (AEFI) with coronavirus disease 2019 (COVID-19) Moderna vaccine.

17 Jan 2022

International approaches to tackling food fraud

In this interview, we spoke to key members of the Food Authenticity Network to find out more about the increasing problem of food adulteration and the collaborations being made to address it.

From Bruker BioSpin Division 11 Jan 2022

Mathematical modeling the vaccination of children against SARS-CoV-2

Researchers evaluated the safety of mRNA vaccination against SARS-CoV-2 in children using mathematical modeling.

10 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Clear, specific product labeling for sesame is crucial to prevent anaphylaxis

In 2021, the US Congress passed the Food Allergy Safety, Treatment, Education & Research Act which, among other things, added sesame to the list of allergens which are mandatory for inclusion on food labels by 2023.

15 Dec 2021

Temporary suspension of 15-minute observation period after vaccination to accelerate booster program

The 15 minute observation period following a vaccination with Pfizer or Moderna will be temporarily suspended as part of new measures to speed up the booster rollout as part of our emergency response to the rapid spread of the Omicron variant.

14 Dec 2021

Can you take the COVID-19 and Influenza vaccines on the same day?

Scientists have conducted a substudy within a phase 3 UK trial and have reported the safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with licensed seasonal influenza vaccines.

19 Nov 2021

Three doses of COVID-19 mRNA vaccination safe in high-risk populations

A new study determines the safety of an additional vaccine among individuals who previously received two doses of mRNA-based COVID-19 vaccines.

15 Nov 2021

Maternal pre-pregnancy BMI linked to pediatric allergic disease development

A University of Ottawa-led study of nearly 250,000 children in Ontario over seven years – the largest of its kind – found a mother's weight before pregnancy may impact their newborn's risk of developing allergic diseases in early childhood, whereas weight gain during pregnancy did not seem to have the same effect.

1 Nov 2021

Anaphylaxis News and Research

Further Reading

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Assessing potential allergic reactions in COVID-19 vaccinated patients

Two peanut allergy treatments for children found to be highly effective at inducing remission

Vaccine hypersensitivity in children

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

International approaches to tackling food fraud

Mathematical modeling the vaccination of children against SARS-CoV-2

Oral bacteria-based SARS-CoV-2 vaccine platform

Clear, specific product labeling for sesame is crucial to prevent anaphylaxis

Temporary suspension of 15-minute observation period after vaccination to accelerate booster program

Can you take the COVID-19 and Influenza vaccines on the same day?

Three doses of COVID-19 mRNA vaccination safe in high-risk populations

Maternal pre-pregnancy BMI linked to pediatric allergic disease development

Medical staff with a history of allergy suffered adverse reactions to BNT162b2 COVID-19 vaccine

COVID-19 vaccine-related allergies are rare, typically mild and treatable, finds study

Researchers find no serious health effects linked to mRNA COVID-19 vaccines

FDA approves an intravenous medication to treat patients with Pompe disease

Study reports on COVID-19 vaccine-related adverse events in young Japanese population

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News